GSK Malaria Vaccine Disappoints In Phase III Africa Trials, But Continues
This article was originally published in PharmAsia News
GlaxoSmithKline's RTS,S/AS01 malaria vaccine demonstrated only modest results in a Phase III trial on African children, a setback for what would be the first preventative for the disease more than 20 years in the making.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.